BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
We have three internally-developed late-stage clinical drug candidates:
- Zanubrutinib (BGB-3111) — an investig...
|Stock Quote||more >|
05/22/18 9:30 a.m. ET
Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Recent Press Releases||more >|
|BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer - May 17, 2018|
|BEIJING, China and CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage ... Read More|
|BeiGene to Present at the 2018 UBS Global Healthcare Conference - May 15, 2018|
|CAMBRIDGE, Mass. and BEIJING, China, May 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage ... Read More|